Assessment of cardiovascular disease risk in rheumatoid arthritis

Tate M. Johnson, Ted R. Mikuls, Bryant England

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Objective: To review cardiovascular disease (CVD) risk assessment in patients with rheumatoid arthritis (RA). Methods: Literature review of the assessment of CVD risk in RA. Results: CVD is the leading cause of death among RA patients. Because of the increased risk of CVD events and CVD mortality in patients with RA, regular assessment of CVD risk and aggressive management of CVD risk in these patients is crucial. CVD risk estimation typically centers on the use of well-established CVD risk calculators. Most CVD risk scores from the general population do not contain RA-related factors predictive of CVD but have had more extensive performance testing, while novel RA-derived CVD risk scores that incorporate RA-related factors have had limited external validity testing. Neither set of risk scores incorporates novel imaging modalities or serum biomarkers, which are most likely to be helpful among individuals at intermediate risk. Conclusion: Primary care and rheumatology providers must be aware of the increased risk of CVD in RA, a risk that approaches that of diabetic patients. Routine assessment of CVD risk is an essential first step in minimizing CVD risk in this population. Until the performance of RA-specific CVD risk scores can be better established, we recommend the use of nationally endorsed CVD risk scores, with the frequency of reassessment based on CVD risk.

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalJournal of Clinical Outcomes Management
Volume26
Issue number1
StatePublished - Jan 1 2019

Fingerprint

Rheumatoid Arthritis
Cardiovascular Diseases
Risk Management
Rheumatology
Population
Cause of Death
Primary Health Care
Biomarkers

Keywords

  • Cardiovascular disease
  • Cardiovascular risk assessment
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Health Policy

Cite this

Assessment of cardiovascular disease risk in rheumatoid arthritis. / Johnson, Tate M.; Mikuls, Ted R.; England, Bryant.

In: Journal of Clinical Outcomes Management, Vol. 26, No. 1, 01.01.2019, p. 41-47.

Research output: Contribution to journalReview article

@article{4867021b410848aea69e092f9b492e89,
title = "Assessment of cardiovascular disease risk in rheumatoid arthritis",
abstract = "Objective: To review cardiovascular disease (CVD) risk assessment in patients with rheumatoid arthritis (RA). Methods: Literature review of the assessment of CVD risk in RA. Results: CVD is the leading cause of death among RA patients. Because of the increased risk of CVD events and CVD mortality in patients with RA, regular assessment of CVD risk and aggressive management of CVD risk in these patients is crucial. CVD risk estimation typically centers on the use of well-established CVD risk calculators. Most CVD risk scores from the general population do not contain RA-related factors predictive of CVD but have had more extensive performance testing, while novel RA-derived CVD risk scores that incorporate RA-related factors have had limited external validity testing. Neither set of risk scores incorporates novel imaging modalities or serum biomarkers, which are most likely to be helpful among individuals at intermediate risk. Conclusion: Primary care and rheumatology providers must be aware of the increased risk of CVD in RA, a risk that approaches that of diabetic patients. Routine assessment of CVD risk is an essential first step in minimizing CVD risk in this population. Until the performance of RA-specific CVD risk scores can be better established, we recommend the use of nationally endorsed CVD risk scores, with the frequency of reassessment based on CVD risk.",
keywords = "Cardiovascular disease, Cardiovascular risk assessment, Rheumatoid arthritis",
author = "Johnson, {Tate M.} and Mikuls, {Ted R.} and Bryant England",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "26",
pages = "41--47",
journal = "Journal of Clinical Outcomes Management",
issn = "1079-6533",
publisher = "Turner White Communications Inc.",
number = "1",

}

TY - JOUR

T1 - Assessment of cardiovascular disease risk in rheumatoid arthritis

AU - Johnson, Tate M.

AU - Mikuls, Ted R.

AU - England, Bryant

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To review cardiovascular disease (CVD) risk assessment in patients with rheumatoid arthritis (RA). Methods: Literature review of the assessment of CVD risk in RA. Results: CVD is the leading cause of death among RA patients. Because of the increased risk of CVD events and CVD mortality in patients with RA, regular assessment of CVD risk and aggressive management of CVD risk in these patients is crucial. CVD risk estimation typically centers on the use of well-established CVD risk calculators. Most CVD risk scores from the general population do not contain RA-related factors predictive of CVD but have had more extensive performance testing, while novel RA-derived CVD risk scores that incorporate RA-related factors have had limited external validity testing. Neither set of risk scores incorporates novel imaging modalities or serum biomarkers, which are most likely to be helpful among individuals at intermediate risk. Conclusion: Primary care and rheumatology providers must be aware of the increased risk of CVD in RA, a risk that approaches that of diabetic patients. Routine assessment of CVD risk is an essential first step in minimizing CVD risk in this population. Until the performance of RA-specific CVD risk scores can be better established, we recommend the use of nationally endorsed CVD risk scores, with the frequency of reassessment based on CVD risk.

AB - Objective: To review cardiovascular disease (CVD) risk assessment in patients with rheumatoid arthritis (RA). Methods: Literature review of the assessment of CVD risk in RA. Results: CVD is the leading cause of death among RA patients. Because of the increased risk of CVD events and CVD mortality in patients with RA, regular assessment of CVD risk and aggressive management of CVD risk in these patients is crucial. CVD risk estimation typically centers on the use of well-established CVD risk calculators. Most CVD risk scores from the general population do not contain RA-related factors predictive of CVD but have had more extensive performance testing, while novel RA-derived CVD risk scores that incorporate RA-related factors have had limited external validity testing. Neither set of risk scores incorporates novel imaging modalities or serum biomarkers, which are most likely to be helpful among individuals at intermediate risk. Conclusion: Primary care and rheumatology providers must be aware of the increased risk of CVD in RA, a risk that approaches that of diabetic patients. Routine assessment of CVD risk is an essential first step in minimizing CVD risk in this population. Until the performance of RA-specific CVD risk scores can be better established, we recommend the use of nationally endorsed CVD risk scores, with the frequency of reassessment based on CVD risk.

KW - Cardiovascular disease

KW - Cardiovascular risk assessment

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85066940910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066940910&partnerID=8YFLogxK

M3 - Review article

VL - 26

SP - 41

EP - 47

JO - Journal of Clinical Outcomes Management

JF - Journal of Clinical Outcomes Management

SN - 1079-6533

IS - 1

ER -